Literature DB >> 33750478

The increasing expression of GPX7 related to the malignant clinical features leading to poor prognosis of glioma patients.

Jiawei Yao1,2, Xin Chen1,2, Zhendong Liu1,2, Ruotian Zhang1,2, Cheng Zhang3, Quan Yang1,2, Penglei Yao1,2, Qiuyi Jiang1,2, Jianing Wu4,5, Shiguang Zhao6,7,8,9.   

Abstract

BACKGROUND: Glioma is the most common malignant brain tumor in adults. The standard treatment scheme of glioma is surgical resection combined alternative radio- and chemotherapy. However, the outcome of glioma patients was unsatisfied. Here, we aimed to explore the molecular and biological function characteristics of GPX7 in glioma.
METHODS: The multidimensional data of glioma samples were downloaded from Chinese Glioma Genome Atlas (CGGA). RT-qPCR method was used to identify the expression status of GPX7. Kaplan-Meier curves and Cox regression analysis were used to explore the prognostic value of GPX7. Gene Set Enrichment Analysis (GSEA) was applied to investigate the GPX7-related functions in glioma.
RESULTS: The results indicated that the expression of GPX7 in glioma was higher compared to that in normal brain tissue. Univariate and multivariate Cox regression analyses confirmed that the expression value of GPX7 was an independent prognostic factor in glioma. The GSEA analysis showed that GPX7 was significantly enriched in the cell cycle pathway, ECM pathway, focal adhesion pathway, and toll-like receptor pathway.
CONCLUSIONS: The GPX7 was recommended as an independent risk factor for patients diagnosed with glioma for the first time and GPX7 could be potentially used as the therapy target in future. Furthermore, we attempted to explore a potential biomarker for improving the diagnosis and prognosis of patients with glioma.

Entities:  

Keywords:  Biomarker; GPX7; Glioma; Survival

Year:  2021        PMID: 33750478      PMCID: PMC7945363          DOI: 10.1186/s41016-021-00235-3

Source DB:  PubMed          Journal:  Chin Neurosurg J        ISSN: 2057-4967


  4 in total

1.  A Bioinformatic Analysis: The Overexpression and Prognostic Potential of GPX7 in Lower-Grade Glioma.

Authors:  Qianqian Zhao; Luyu Zhang; Yingying Wang; Ye Sun; Tianpei Wang; Jingjing Cao; Meng Qi; Xiaoping Du; Zengrun Xia; Rongqiang Zhang; Yin Yang
Journal:  Int J Gen Med       Date:  2022-04-21

2.  GPX7 Is Targeted by miR-29b and GPX7 Knockdown Enhances Ferroptosis Induced by Erastin in Glioma.

Authors:  Yan Zhou; Haiyang Wu; Fanchen Wang; Lixia Xu; Yan Yan; Xiaoguang Tong; Hua Yan
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

3.  Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas.

Authors:  Wallax Augusto Silva Ferreira; Glauco Akelinghton Freire Vitiello; Tiago da Silva Medina; Edivaldo Herculano Correa de Oliveira
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

4.  GPX8 as a Novel Prognostic Factor and Potential Therapeutic Target in Primary Glioma.

Authors:  Zhao-Shou Yang; Qin Yang; Xiao-Xiao Sun; Kui Xiong; Xiao-Ting Zhu; Yi-Chen Wang; Qian-Yao Ren; Guo-Hui Wu; Shi-Min Wang; Xu-Qin Cao; Xiao-Rong Yang; Wen-Gong Jiang
Journal:  J Immunol Res       Date:  2022-08-23       Impact factor: 4.493

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.